Integrative CRISPR-Cas9 dependency analysis identifies CDC45 as a candidate prognostic biomarker with preliminary functional validation in prostate adenocarcinoma
Abstract
Prostate adenocarcinoma (PRAD) has become one of the most prevalent malignancies in men worldwide. Although advances in diagnostic techniques and targeted therapies have improved clinical outcomes, a significant subset of patients still develops aggressive, metastatic disease with limited treatment options. At present, identifying reliable biomarkers for early risk stratification remains a critical unmet need in prostate cancer research. This study presents a dependency-informed prognostic prioritization approach by integrating multi-omics data to enhance clinical risk stratification in prostate adenocarcinoma (PRAD). Integrated analysis of CRISPR-Cas9 dependency screens and bulk RNA sequencing data prioritized tumor-dependent genes associated with PRAD cell viability. Pathway enrichment analysis indicated the involvement of these candidate genes in cell cycle regulation and tumor progression. Subsequently, an 11-gene prognostic signature was constructed via LASSO regression, effectively stratifying patients, with the high-risk cohort demonstrating significantly reduced Progression-Free Interval (PFI; log-rank p < 0.001). Among the prioritized hub genes, CDC45 exhibited marked upregulation in tumor tissues, which was confirmed by Western blotting and qRT-PCR. Collectively, this study provides a dependency-informed prognostic framework for PRAD and nominates CDC45 as a candidate prognostic biomarker, laying the groundwork for future mechanistically resolved investigations.